Dutasteride (0.5mg)

DRUG3 trials

Sponsors

GlaxoSmithKline, Universitas Diponegoro, Paul Toren

Conditions

BPH (Benign Prostatic Hyperplasia)Bladder CancerProstatic Hyperplasia

Phase 1

Bioavailability of Two Combination Products of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) in Asian Males.

CompletedNCT01471678

GlaxoSmithKlineProstatic Hyperplasia

Start: 2011-06-30End: 2011-09-07Updated: 2018-06-19

Effetivity of Dutasteride and Aloe Vera Extract Combination on Angiogenesis and Obstruction on Benign Prostatic Hyperplasia

RecruitingNCT07065682

Universitas DiponegoroBPH (Benign Prostatic Hyperplasia)

Start: 2023-07-01End: 2027-12-01Target: 84Updated: 2025-07-15

Phase 2

Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer

RecruitingNCT07420517

Paul TorenBladder Cancer

Start: 2026-03-25End: 2032-04-02Target: 95Updated: 2026-03-30

Related Papers

Pharmacokinetic bioequivalence studies of a fixed-dose combination of tamsulosin and dutasteride in healthy volunteers.

2014-05-015 citations